The next Alnylam? RNAi biotech City Therapeutics files for IPO
Why now
Thesis: Another RNAi IPO tests biotech listing appetite
Catalyst to watch: IPO pricing and first-day trading
Main risk: Early-stage biotech listings can flop
Why it matters
A new RNAi biotech IPO filing adds a single early-stage issuer to the biotech pipeline, with no disclosed pricing or terms.
Sources
- googlenews · news.google.com · 2026-09-25 11:04 UTC